|Bid||1.50 x 1000|
|Ask||2.05 x 4000|
|Day's Range||1.82 - 1.95|
|52 Week Range||1.55 - 6.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2017 - Jul 31, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today receipt of a cash milestone from Incyte for the initiation of a Phase 1 clinical trial of INCAGN2385, an anti-LAG-3 antibody discovered by Agenus. Based on this milestone and under the terms of the agreement, Agenus received a $5 million payment and is eligible to receive up to an additional $505 million in potential development, regulatory and commercial milestones from Incyte. "This is the fourth antibody from our partnered programs that has advanced into clinical trials, once again proving our commitment to deliver on our existing partnerships," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.
- Both TCRs discovered by Novel "T-Rx™" Discovery Platform LEXINGTON, Mass. , Sept. 5 , 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing ...
LEXINGTON, Mass. , Sept. 4, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies ...
Zacks.com featured highlights include: Dollar Tree, Agenus, Huntsman, ArcelorMittal and International Paper
LEXINGTON, Mass., Aug. 15, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that Merck, known as MSD outside the United States and Canada, initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration. Based on this milestone and under the terms of the agreement, Agenus received a $4 million milestone payment and is entitled to receive up to an additional $95 million in success milestones from Merck. "We continue to deliver on all milestones with our existing partners." said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Agenus (AGEN) delivered earnings and revenue surprises of 36.84% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 24 cents. The company's shares closed at $1.75. A year ago, they were trading at $3.85. _____ This story was generated ...
- Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more than 115 patients; clinical benefit confirmed LEXINGTON, Mass. , Aug. ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time. To listen ...
LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , ...
In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cadence ...
Biotechs are infamous for tapping the public markets for capital on a regular basis. Here is a look at how this standard practice can both damage and create value for shareholders.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...